18th May 2016 16:11
LONDON (Alliance News) - GlaxoSmithKline PLC and Innoviva Inc Wednesday announced new data from its SUMMIT study of Breo Ellipta in chronic obstructive pulmonary disease at the American Thoracic Society conference in San Francisco.
Data from one analysis of the SUMMIT trial, or the Study to Understand Mortality and Morbidity showed that patients with COPD and moderate airflow limitation receiving the treatment achieved improvements in exacerbations compared to a placebo, and a second analysis showed patients reported similar rates of pneumonia whilst taking the drug compared with a placebo.
Additionally, the two companies also released new efficacy data for Anoro Ellipta for patients with chronic obstructive pulmonary disease who had continued to have symptoms when treated with tiotropium.
The new data showed that patients who were switched from tiotropium saw a "statistically significant improvement" for the primary endpoint of lung function at the twelfth week compared to patients who remained on tiotropium.
Shares in GlaxoSmithKline closed down 0.2% at 1,4441.17 pence Wednesday.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline